In Vivo Antifungal Activity and Computational Studies of Some Azole Derivatives against Candida Albicans

Table 2

Anticandidal activity of compounds 1–15 in comparison with fluconazole and control using obtained CFU/kidney.

Compound	Dose (mg/kg)	No of colony (compound/fluconazole)	No of colony (compound/control)	CFU (±SD)
1	10	8.23	1.59^NS	799.29 (85.25)
	20	11.2	0.76	382.92 (54.10)
	50	9	0.27	137.97 (21.12)
2	10	2.5	0.48	242.80 (15.23)
	20	1.05^NS	0.07	35.89 (5.21)
	50	3.50^NS	0.1	53.65 (8.94)
3	10	4.15	1.38	403.04 (71.25)
	20	1.72^NS	0.11	58.80 (15.44)
	50	1.00^NS	0.03	15.33 (2.31)
4	10	4.41	0.85	428.29 (44.36)
	20	5	0.34	170.95 (21.87)
	50	3	0.09	45.99 (8.91)
5	10	8.75	1.69	849.80 (56.98)
	20	18.4	1.25	629.09 (55.21)
	50	17	0.52	260.61 (25.25)
6	10	9.75	1.89	946.92 (101.43)
	20	16	1.09	547.04 (32.65)
	50	20	0.61	306.60 (10.12)
7	10	2.27	0.44	220.46 (11.85)
	20	5.73	0.31	159.90 (16.37)
	50	11.04	0.33	169.24 (29.56)
8	10	1.8^NS	0.35	174.81 (27.38)
	20	3.21^NS	0.22	109.74 (28.46)
	50	2.1^NS	0.06	32.19 (8.95)
9	10	2.74	0.53	266.8 (43.27)
	20	4.72	0.32	161.37 (50.66)
	50	12.33	0.37	189.16 (27.44)
10	10	3.80	0.70	369.05 (20)
	20	3.98	0.27	136.07 (7.76)
	50	11.87	0.36	181.96 (7.21)
11	10	3.88	0.75	376.82 (22.17)
	20	6.31	0.43	215.73 (19.34)
	50	12.92	0.39	198.06 (8.37)
12	10	6.25	1.21	607.00 (65.59)
	20	4.5	0.30	153.85 (11.85)
	50	G	0.05	—
13	10	105.2	1.58^NS	G
	20	59.25	0.36^NS	G
	50	G	—	G
14	10	G	—	G
	20	G	—	G
	50	G	—	G
15	10	4.16	0.80	404.01 (61.44)
	20	1.25^NS	0.08	42.73 (6.87)
	50	1.25^NS	0.03	19.16 (3.27)
Fluconazole	10	1	0.19	97.12 (5.66)
	20	1	0.06	34.19 (3.36)
	50	1	0.03	15.33 (1.86)
Control				500 (5)

CFU = colony-forming unit, SD = standard deviation, , , NS = not significant, and G = growth.